Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19)
Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
COVID-19 TESTING
CLINICAL therapeutics
AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
SAN DIEGO – December 14, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller...
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
SAN DIEGO, December 3, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an...
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, applauds the recent announcement from a major...